Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:20
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 29 条
[1]   Ewing's sarcoma ONLY PATIENTS WITH 100% OF NECROSIS AFTER CHEMOTHERAPY SHOULD BE CLASSIFIED AS HAVING A GOOD RESPONSE [J].
Albergo, J. I. ;
Gaston, C. L. ;
Laitinen, M. ;
Darbyshire, A. ;
Jeys, L. M. ;
Sumathi, V. ;
Parry, M. ;
Peake, D. ;
Carter, S. R. ;
Tillman, R. ;
Abudu, A. T. ;
Grimer, R. J. .
BONE & JOINT JOURNAL, 2016, 98B (08) :1138-1144
[2]  
Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra
[3]  
[Anonymous], 2006, PROT EUR EW 99
[4]   Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology [J].
Arpaci, Erkan ;
Yetisyigit, Tarkan ;
Seker, Metin ;
Uncu, Dogan ;
Uyeturk, Ummugul ;
Oksuzoglu, Berna ;
Demirci, Umut ;
Coskun, Ugur ;
Kucukoner, Mehmet ;
Isikdogan, Abdurrahman ;
Inanc, Mevlude ;
Alkis, Necati ;
Ozkan, Metin .
MEDICAL ONCOLOGY, 2013, 30 (01)
[5]  
Bacci G, 2004, ONCOL REP, V11, P111
[6]   The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy [J].
Bacci, G ;
Longhi, A ;
Briccoli, A ;
Bertoni, F ;
Versari, M ;
Picci, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03) :766-772
[7]   Developing a Prognostic Model for Localized Ewing Sarcoma Family of Tumors: A Single Institutional Experience of 224 Cases Treated With Uniform Chemotherapy Protocol [J].
Biswas, Bivas ;
Rastogi, S. ;
Khan, S. A. ;
Shukla, N. K. ;
Deo, S. V. S. ;
Agarwala, S. ;
Mohanti, B. K. ;
Sharma, M. C. ;
Vishnubhatla, Sreenivas ;
Bakhshi, S. .
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (06) :683-689
[8]   Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group [J].
Cotterill, SJ ;
Ahrens, S ;
Paulussen, M ;
Jürgens, HF ;
Voûte, PA ;
Gadner, H ;
Craft, AW .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3108-3114
[9]   The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models [J].
de Wreede, Liesbeth C. ;
Fiocco, Marta ;
Putter, Hein .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2010, 99 (03) :261-274
[10]   Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database [J].
Duchman, Kyle R. ;
Gao, Yubo ;
Miller, Benjamin J. .
CANCER EPIDEMIOLOGY, 2015, 39 (02) :189-195